Seetulsingh P S, Hall L M, Livermore D M
Department of Medical Microbiology, London Hospital Medical College, UK.
J Antimicrob Chemother. 1991 Jun;27(6):749-59. doi: 10.1093/jac/27.6.749.
Recent reports of decreased susceptibility to amoxycillin/clavulanate and ticarcillin/clavulanate combinations amongst Escherichia coli isolates have been attributed to an increased frequency of hyperproduction of TEM-1 beta-lactamase. To test this claim we compared the activities of clavulanate combinations against consecutive E. coli isolates producing TEM-1 beta-lactamase that were obtained from clinical material at The London Hospital during 1982 (n = 50) and 1989 (n = 46). Enzyme production was quantified and related to the level of clavulanate required to potentiate amoxycillin and ticarcillin. The levels of TEM-1 enzyme production varied 150-fold amongst the isolates, partly because of variation in the gene copy number. A clear correlation existed between enzyme quantity and levels of resistance to the clavulanate combinations. However, there was no significant difference (P greater than 0.05, Mann-Whitney U test) between the isolates obtained in 1982 and 1989 in terms of the clavulanate concentrations required to potentiate the penicillins, or in the distribution of beta-lactamase activities present.
最近有报道称,大肠杆菌分离株对阿莫西林/克拉维酸和替卡西林/克拉维酸组合的敏感性降低,这归因于TEM-1β-内酰胺酶高产频率的增加。为了验证这一说法,我们比较了克拉维酸组合对1982年(n = 50)和1989年(n = 46)从伦敦医院临床材料中获得的连续产生TEM-1β-内酰胺酶的大肠杆菌分离株的活性。对酶的产生进行了定量,并将其与增强阿莫西林和替卡西林所需的克拉维酸水平相关联。在这些分离株中,TEM-1酶的产生水平相差150倍,部分原因是基因拷贝数的变化。酶的数量与对克拉维酸组合的耐药水平之间存在明显的相关性。然而,就增强青霉素所需的克拉维酸浓度或存在的β-内酰胺酶活性分布而言,1982年和1989年获得的分离株之间没有显著差异(P>0.05,曼-惠特尼U检验)。